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1Traditional Chinese herbal medicine has recently enjoyed a dramatic increase
in popularity in the United States, however, currently, it is not specically reg-
ulated by the Food and Drug Administration (FDA). The FDA policy towards
Chinese herbal medicine at the present time is one of non-action until complaints
about a product are led, at which point the FDA can then decide to take cer-
tain steps within its enforcement powers, including issuing warning letters and
import alerts, removing the product from the market through seizures, and pros-
ecuting the manufacturers. Nevertheless, this wait-and-see policy allows both
imported and domestically produced Chinese herbal medicines to oat freely in
Asian shops as well as in general health food stores without FDA oversight, at
least until complaints are lodged. This is troublesome because there are real
and present dangers involved with the use of Chinese herbal medicines that
militate for a more proactive role to be undertaken by the FDA. I will begin
this discussion by describing traditional Chinese medicine and how it compares
to the Western medical tradition. Second, I will then examine why regulation
is necessary given the impact of Chinese herbal medicine on American health-
care. Then, I will proceed to the problem of trying to t a square peg into
a round hole, namely, the issue of regulating Chinese herbal medicine under
current statutory provisions. Fourth, I will analyze state and federal responses
to alternative therapies in general and Chinese herbal medicine in particular,
afterwards focusing on the FDA's piecemeal approach thus far. Finally, I will
examine two potential models for reform, Germany and Canada, to see if there
are lessons to be leamed from their practices.
1
2I. Introduction to Traditional Chinese Medicine
A. Traditional Chinese Medicine: A Brief History
The beginning of documented Chinese medicine can be traced to fourteen
manuscripts on various aspects of health care dating back to 167 B.C., discovered
in an excavated tomb at the Ma-wang-tui site in Hunan province in 1972.1
Pharmaceutical knowledge was rst found recorded in the Ma-wang-mi scripts,
in a work known as Pr~ripIi~n~ Against 52 Ailments ( Wu-shih-erh ping fang)
and chronicled a signicant shift in our
2
understanding of the Chinese approach to illness and disease. The manuscripts
signaled
an important turning point: the incipient development of a system of health
care beliefs and practices that shifted away from a metaphysical emphasis on
an individual's
interactions with his ancestors towards a greater emphasis on the concrete
illnesses of the
3
human mind and body. Up to this time, approximately the second century B.C.,
a
person's health was thought to depend upon interactions with one's ancestors.4
Following certain norms of conduct was believed to assure health and well-being,
while a failure to do so incited the wrath of the dead ancestors, which could
manifest itself in the form of disease and illness.5 The ancestral spirits had to
then be appeased with sacrices.6
1Paul Unschuld, History of Chinese Medicine, in The Cambridge World History of
Human Di~a~, at 21 (Kenneth Kiple ed., 1983).
2 Id. at 21.
31d.at2O.
2
3By the rst century, various divergent schools of medical thought had emerged,
and were compiled in the classic text that has profoundly shaped Chinese medi-
cal thought, The Yellow Emperor's Classic of Internal Medicine, (Huang-ti nel-chingY'
Traditional Chinese medical treatment, with roots dating back millennia, is
premised on the concept that the human body is a unied organic entity, a
microcosm of the socioeconomic structure of the Chinese empire, with dierent
units performing its own tasks and channeling resources from the outside and
those developed from within
8
throughout the body. The resources distributed throughout the body were
designated as ch 'i in The Yellow Emperor's Classic of Internal Medicine, and
referred to vital vapors
essential to the organism's existence.9 The invisible dz..i, or vital energy,
circulates through a system of conduits, the principal ones being the meridians
or channels, as well as through the blood.'0 This idea echoes analogous early
European concepts, such as the spiritus, and both may have originated from
observations of phenomena such as
suocation and empty vessels (i.e. arteries, derived from aer tereo, carriers
of air) in
II
a corpse.
Like all medicine, the purpose of Chinese medicine is health, and in Ih~..Y~1k~
Emperor's Classic of Internal Medicine, a generally healthy person who lived a
Id. The precise date of composition and authorship of The Yellow Emperor's Classic of Internal Medicine
is a subject of debate. ~ The Yellow Emperor's Classic of Internal M~dkin~ at 6
(lIza Veith trans., 1972). |8 of Traditional Chinese Medicine. Vol. 2: Clinical
E.g., Liu Yangchi, The Essential Book
Pra~tk~ at 1 (Fang Tingyu and Chen Laidi trans., 1988); ~~nlsQ, Unshuld,
supra note 1, at 21.
10 Ralph Alan Dale, The Forms of Qi (Vital Energy) in Acupuncture,
American Journal of
A~upun~~r~
Vol. 22, (1994).
Unschuld, supra note 1, at 21.
3
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temperate life was believed to have a life span of one hundred years. The
work explicitly acknowledged that lifestyle was a factor in a person's health and
longevity.'3 As a result, there is an emphasis in The Yellow Emperor's Classic of
Internal Medicine on preventive medicine.'4 This emphasis on prevention is also
implied in the rst Chinese exclusively herbal work, generally agreed to have
been compiled in the rst century, Ih~ Divine Husbandman's Classic on Materia
Medica (Shen-nungoen-ts 'pp ching).'5 In Th~ Divine Husbandman's Classic on Materia Medica,
the legendary sage Shen Nung is depicted as an experimentalist who tasted dif-
ferent plants and classied them according
16
to their nature and their eects for medicinal purposes. The 365 plants
described in the
work are divided into three categories, superior, medium, and inferior, de-
termined by their rejuvenating, tonic, or curative properties.'7 Since the reju-
venating plants were
deemed the superior, this suggests again that prevention was more highly
regarded than
18
curing in traditional Chinese medicine.
12
The Yellow Emperor's Classic of Internal Medicine, supra note 2, at 97-98.
13 The author states that the ancients were able to live past one hundred
years of age because [t]here was temperance in eating and drinking. Their hours
of rising and retiring were regular and not disorderly and wild. Id. at 97.
14 In the work, the author comments To administer medicines to diseases
which have already developed and to suppress revolts which have already de-
veloped is comparable to the behavior of those persons who begin to dig a well
after they have become thirsty, and of those who begin to cast weapons after
they have already engaged in battle. Would these actions not be too late? Id.
at 105.
15 Id. Here again, the exact date and authorship is unclear. Id.
16
Lu Gwei-Djen & Joseph Needham, A Contribution to the History of Chinese
Dietetics, in Science & Technology in East Asia at 86 (Nathan Sivin, ed., 1977).
'7Id.
18
Id. Interestingly, Lu and Needham believe that credit for the discovery of
the importance of diet and its relation to certain deciency diseases should be
given to Chinese civilization. Id. at
91.
4
5There is a dichotomy in the methods of treatment found in traditional Chinese
medicine, which can be characterized as the medicines of systematic correspon-
dence, and
that of pragmatic drug therapy.'9 The dichotomy may be a result of the
rivalry between
20
the Confucian-Legalist school and the Taoist worldview. The Confucian-
Legalists
believed in a social order maintained by appropriate legal and moral behav-
ior, hence they
encouraged medicine based on systematic correspondence, which promised
health to
21
those who followed a correct lifestyle. Pharmaceutical relief, however, was ob-
tainable
by anyone, regardless of their lifestyle or morality, and so was more closely
tied to Taoism, which rejected the rigidity of Confucian standards of behavior
and thought.22 The philosophy of systematic correspondence held that there
was a relationship between all things in the universe, which could be placed
into two (yin-yang) or ve (ve phases)
23
categories for all phenomena. The yin-yang school assumes an antagonistic
unity
between the dierent entities in the universe, e.g. day and night, male and
female, heaven
24
and earth. Around the fourth century B.C., certain terms including day,
male, and
heaven, were deemed qualitatively identical and described as yang, while
their opposites,
25
night, female, earth, were called yin. The ve phases school identied ve
groupings
of qualitatively identical phenomena symbolized by ve elements: metal,
wood, water, re, and soil, which also was thought to correspond to the ve
major organs of the body:
19 Unschuld, supra note 1, at 23.
20Id.
21Id.
22Id.
Id at 24.
2414.
25Id.
5
626
lungs (metal), liver (wood), kidneys (water), heart (re), spleen (soil). On
the other
hand, The Divine Husbandman's Classic on Materia Medica contained almost
no
27
reference to systematic correspondence. Traditional Chinese pharmaceutics
grew from
the 365 substances documented in The Divine Husbandman's Classic on Materia Medica
to 850 compounds in the rst government-backed collection of herbal sub-
stances in 659,
28
to the over 1,700 drug descriptions published from 960 to 1126. When the
seminal text,
~ (arranged according to drug descriptions and technical aspects), (~z
t,~j~angizw), was published in 1596 by Li Shih-chen, it boasted more than
1,800 drug
29
monographs and more than 11,000 prescriptions in 52 volumes. The break
between the
two major traditions of Chinese medicine, systematic correspondence and
pragmatic therapy, was closed by the thirteenth century, however, when scholars
such as K'ou
Tsung-shih, Chang Yuan-su, and Wang Haogu, began developing a pharma-
cology based
30
on systematic correspondence. Chinese herbal pharmacology was henceforth
classied
based on the philosophy of systematic correspondence.
B. Traditional Chinese Medicine: Denitions
Traditional Chinese medicine refers to a health care system with an array of
treatment options besides herbal medicine, including acupuncture, moxibustion,
Tui Na, Tai Chi, Qui Gong, which will be addressed briey. Acupuncture is rst
referred to in Chinese literature in 90 B.C., but its origins are unclear.3' It may
have arisen from
26 The Yellow Emperor's Classic of Internal Medicine, supra note 7, at 21.
27 Unschuld, supra note 1 at 21.
2814
14. at 25.
3O~
31 Id.at 23.
6
7attempts to pierce regions of the body thought to be overrun by some kind of
outside evil
32
with symbolic swords. Acupuncture made its widespread debut in the U.S. in
1971, when James Reston reported in the New York Times how physicians in
Beijing had
alleviated his post-surgery abdominal pains with acupuncture?~ Acupunc-
ture has won adherents for its usefulness in helping to ease chronic pain, arthri-
tis, post-surgery nausea, migraines and fatigue.34 It has been reported that
an estimated 15 million Americans have tried acupuncturei In 1993 the FDA
declared that Americans spent $500 million a
36
year on an estimated 9 million to 12 million visits for acupuncture therapy.
Thirty
states have legalized acupuncture and more than 20 acupuncture schools
have been accredited by the U.S. Department of Education.37 In March 1996,
the FDA classied acupuncture needles as class II medical devices, removing a
major barrier to insurance coverage, although it is still too early to know with
certainty whether this ruling will
38
automatically qualify acupuncture treatments for insurance coverage. Under
the new classication, as with other class II medical devices, the needles are
required to have
proper labeling and good manufacturing practices.39 Needle manufacturers
will have to submit documents regarding the materials used and the needles are
required to have prescription labels restricting use to qualied practitioners as
determined by individual
32 Id. at 21.
Caryle Murphy, Acupuncture Boom: Eastern Technique Is Growing In Pop-
ularity But
Western Scientists Look for More Proof, The Washington Post, October 8,
1996.
341d.
~ Rick Weiss, Los Angeles Times, March 30, 1996, at A-16.
36 Murphy, supra note 33.
37j4~
38 EDA&Qnsu1n~r, June 1996, at 4; s~aJsu Weiss, supra note 35.
7
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states. Although this discussion focuses on Chinese herbal medicines, acupunc-
turists often prescribe Chinese herbal medicines as part of their treatment, so
there is a noteworthy relationship between the acceptance of acupuncture and
that of Chinese herbal medicine. Moxibustion, another form of therapy with
theoretical underpinnings similar to those underlying acupuncture, involves ap-
plying combustible cones of powdered leaves of Artemisia vulgaris (mugwort)
to the skin.41 These cones are ignited on specic locations on the body and left
to bum until a blister is formed.42 Tui Na, another type of therapy, is a form of
massage used to treat muscle injuriesi~ Finally, there are Tai Qi and Qui Gong,
which are types of exercise that apply principles of
traditional Chinese philosophy to strengthen the body and increase a per-
son's level of
44
energy. All of these forms of therapy can and are used in conjunction with
Chinese
herbal medicine.
C. Traditional Classication of Chinese Medicinal Herbs: An Overview
Chinese medicinal herbs, which include plant, animal, and mineral products,
all have properties and avors which are considered together in deciding a course
of
treatment.45 The properties of herbs refer to the sorts of conditions they
treat, developed
46
through centuries of use. The avor of the herbs originated from its taste, when
people long ago tasted them, since in ancient times there was no way to classify
them by
40~
41 The Yellow Emperor's Classic of Internal Medicine, supra note 7, at 58-9.
Id. at 59.
'~ Website of the American College of Traditional Medicine.
Id.
'~ Yanchi, supra note 8, at 43-44.
461d.at44.
8
9chemical composition.47 Each medicinal herb has one of four properties
depending on its
48
therapeutic eects: cold, hot, warm, or cool. Hot diers from warm and cold
diers from cool only in degree, and within each category, various degrees exist
as well.49
Those herbs that eectively treat heat symptom-complexes, such as fevers
and sore throat, are deemed to possess cool or cold properties, while those that
are eective against cold symptom-complexes, such as pathogenic colds or a
weak pulse, are said to have warm or hot properties.50 There are also ve basic
avors medicinal herbs possess:
pungent, sweet, sour, bitter, and salty.51 Also, some herbs are said to be
insipid (lacking
52
in avor), or to cause a puckery sensation. The ve avors are believed to
correspond
to the ve elements and the ve major organs.53 Pungent herbs have a
dispersing action, and promote energy and blood ow, working primarily in the
lung and large intestine. Sweet herbs are tonics and regulate the functions of
the spleen and stomach. Sour herbs
are astringents and stop discharges and diarrhea, eective primarily in the
liver and
56
gallbladder. Puckery herbs have eects similar to sour herbs, and are used
to treat
urinary frequency and bleeding.57 Bitter herbs are used to treat the heart
and small
58
intestine, and are generally good for constipation and restlessness due to
heat. Salty
herbs reduces swelling and relieves constipation, and are eective in treating
the kidney
471d.
48~
491d.
501d.
511d.
52~
531d.at45.
541d.
Id.
56~
571d.
109
11and urinary bladder.59 Insipid herbs treat conditions of dampness, and are used
to treat
60
edema and trouble with urination.
Each herb is also classied as one or more of the following: ascending,
61
descending, oating, and sinking. Ascending and descending refers to the
direction of the activity, and oating herbs disperse pathogenic factors while
sinking herbs have
62
tranquilizing eects. Herbs with ascending and oating characteristics are
used to energize, dispel pathogenic wind and cold, induce vomiting, and to
resuscitate.63 The
functions of herbs with descending and sinking tendencies include promoting
the removal of waste from the bowels, dispelling heat, tranquilizing nerves,
checking the profusion of
vital functions, aiding digestion, and relieving cough and asthmai4 Most
ascending and
65
oating herbs are pungent or sweet in avor, and have warm or hot proper-
ties.
Descending or sinking herbs tend to be sour, bitter, salty or puckery, and
have cold or
66
cool properties.
Precautions are taken by Chinese herbal practitioners when prescribing medic-
inal
67
herbs, as certain herbs are known to have drastic or toxic eects. For exam-
ple, certain herbs should not be prescribed to women who are pregnant because
they are known to
induce abortion, such as Fructus Crotonis, (croton fruit), Moschus (musk),
Hirudo
58~
591d.
60~
61 Id. at46.
63~
65~
66~
671d.at47.
10
12681d.at48.
69 Unschuld, supra note 1, at 24.
7O~
(leech), and Tabanus Bivittatus (gady). Certain dietary prohibitions also
apply when particular herbs are being taken as they might counteract the
medicine, and it is generally recommended that raw, cold, greasy and irritant
foods should be eschewed when taking herbal medicines.68
D. Western Medical Tradition Compared
To say that traditional Chinese medicine has progressed is, strictly speak-
ing, somewhat of a mischaracterization. Notions of progress often implies that
something was left behind, and with traditional Chinese medicine this was sim-
ply not the case.69 Medical knowledge was expanded upon with few changes,
as with the growth in pharmaceutical literature, which saw little change except
for certain herbals being
70
characterized as no longer in use. Major paradigm shifts did not occur in
traditional
Chinese medical science as it did in the West, but this is not to say that tra-
ditional Chinese medical therapies should be rejected on the basis of its failing to
conform with Western scientic sensibilities. Indeed, Western science made its
greatest advances through its adherence to the Baconian scientic method, but
one of the results has been a legacy of distrust and disdain towards knowledge
gleaned without the benet of scientic experiments and careful controls. In
traditional Chinese pharmaceutical medicine, an assortment of plants, animals,
and minerals is made into a mixture to treat a specic individual. This kind of
tailoring of treatment is troublesome to most Western practitioners, who believe
that dosages should generally be relatively uniform and who
11
13are xated with determining the specic eect of each constituent ingredient.71
Disease is viewed as separate from the person in Western medicine, whereas in
Chinese medicine, the two are not so unyieldingly demarcated.
II. Is Regulation of Traditional Chinese Herbal Medicine Necessarv?
A. A Study of Five Sample Products
Chinese herbal medicines can be gotten in three forms: i) some herbs are
available at local Chinese markets and are used in recipes for simple herbal
remedies, acquired
through family and friends; ii) more complex formulas can be procured at
herbal stores
72
and pharmacies. The herbal prescription is usually drawn up by an herbal
practitioner
and formulated to specically match the individual's diagnosis, and the pre-
scription is then lled by the pharmacist who weighs out the correct amount
of herbs.73 At some shops, the pharmacist both prescribes and dispenses the
remedy to the individual.74 The third means by which Chinese herbal remedies
are obtained is through imported prepackaged herbal medicines, also known as
Chinese patent medicines, and sold in pill,
71 e.g., Herbal Pharmacology in the People's Republic of China: A Trip Report of
the American Herbal Pharmacology Delegation, National Academy of Sciences,
at 7 (1975). Perhaps this basic dierence between traditional Chinese and West-
ern medicine stems from divergent views of the world. Nathan Sivin has sug-
gested that the gradual acceptance in the West of the idea of a mechanical uni-
verse with its accompanying notions of causality played a part in the diering
outlooks between traditional Chinese and Western medicine. These mechanis-
tic ideas played a negligible role in traditional Chinese culture and medicine,
which were shaped by ideas of yin-yang, ve phases, and other related concepts.
Science and Technology in East Asia, supra note 16 at xix.
72
Linda Barnes, Alternative Pursuits: A History of Chinese Healing Practices in the Context ot
American Religions and Medicines, with an Ethnographic Focus on the City of
Boston 428 ~1995) (Unpublished Ph.D. dissertation, Harvard University).
Id.at429.
741d.
12
14capsule or tonic form.75 The imported prepackaged medicines make a range of
claims:
from alleviating coughs and colds to treating the most serious of diseases.
The following are ve samples of Chinese herbal medicines readily available for
purchase:76
1. Fare-You (Vitamin U complex). (50 tablets) The latest and most eec-
tive remedy for various sorts of gastric pains, and ulcer and duodenal ulcers.
Qiaoguang Pharmaceutical Factory, Guangzhou, China.
Indication: Treatment of peptic ulcers: as gastric and duodenal ulcers, achylia
gastrica, hyperacidity, chronic gastitis, regurgitatica and lesions in the coats of
the stomach. Dosage: 1-2 tablets each time, Thrice a day.
The insert stated in English and Chinese:
Description:
The preparation of FARE-YOU (Vitamin U complex) is a new special rem-
edy. They are made from the best quality of vitamin U and other ingredients.
These tablets are reputed to be the latest and the most eective medicine for gas-
tric and duodenal ulcers, chronical gastritis and various types of gastropathies.
The disease mentioned above generally are due to the functional irritation of
the gaster or lesions in the coats of the stomach. But nothing can resolve the
diculties of the problem. It is only after the discovery of vitamin U composite
tablets of our laboratory, that a cure is possible for the purpose.
This medicine is a specialty for gastropathies: It provides for the organism with
more proliferative methyl to promote the ulcerated part of gastro-intestinal tis-
sue to accelerate healing. We strongly recommend to use our products TABLETS
FARE-YOU COMPOSITA. Those who are eected with this kind of disease will
be cured quickly, and the disease, will be soon eradicated.
There was no ingredient list in Chinese or English.
2. Fritillaria Verticellata & Loquat. Recommended in dry or spas-
modic cough. Dose:
Half to one tablespoonful. Price: $2.50. Made in Hong Kong.
The insert was only in Chinese.
3. Ganmaoling Tablets. (36 tablets) Made in Qixing Pharmaceutical
Factory,
Guangzhou China. Manufacture Supervised by Guangdong Medicines &
Health
Products Import & Export Corporation. Price: 60 cents.
Actions and Indications: Antipyrec, antiphlogistic and antidotal. Applica-
ble to
common cold and prevention of inuenza, epidemic eicephalitis.
751d.
76 Field research conducted at the Nam Buk Hong pharmacy, 75 Harrison
Avenue, Boston.
January 18, 1997.
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15Direction and Dosage: For adult, four tablets each, three times daily. Double
dosage in
severe cases, children decreased accordingly.
Prevention: Two tablets each, two times daily, to be taken contin-
uously 3 days.
Ingredients: Flos Lonicerac: 4.85%; Flos Chrysanthemi Indici: 13.03%; Se-
men Viticis
Negundo: 13.03%; Radix Isatidis: 13.03%; Folium Et Ramulus Evodiae Leptae:
2 1.72%;
Radix Ilicis Asprellae: 34.33%; Mentholum: 0.01%.
The insert stated in English and Chinese:
Ganmaoling a most eective preparation for the treatment of common cold and
inuenza, is extracted from selected Chinese medicinal herbs by means of scien-
tic method. The chief actions of these medicinal ingredients of Ganmaoling are
antipyretic, antidotal and antiphiogistic. The antipyretic eciencies, is aord-
ing instantaneous relief with eects remarkably marvelous. Clinical observation
has proved that Ganmaoling is excellent in cure and prevention of common cold
and inuenza. It is particularly valuable in the treatment of inuenza with fever
of dierent degrees during the onset of this disease. Usually, a dosage of four
tablets can eectively put under control of all symptoms. Owing to its quick
action and absence of undesirable side eects, both doctors and patients prefer
to use this remedy.
4. Naolutong Capsule. (30 tablets) Naoluotong [sic] is a new product for
treatment of cerebral arter arteriosclerosis. Sequela of cerebral apoplexy and
meningitis, cerebral palsy, spastic myeloglegia, amyotrophic lateral sclerosis.
Price: $5.50.
Dosage: 1-2 capsules each time, 3 times daily.
Made in China by the United Pharmaceutical Manufactory, Kwangchow.
The insert stated the above description in Korean as well. The rest of the
insert was in Chinese, with an ingredient list printed in Chinese but not in
English.
5. Sumalin- Sugar Coated Tablets (100 tablets).
Actions and Uses: Sumalin is remedy for prevention and treatment of coro-
nary heart disease. It reduces elevated plasma cholesterol, triglyceride and B-
lipoprotein levels and dilates coronary artery. It is used in atherosclerosis and
other conditions characterized by high blood cholesterol level, such as angina
pectoris, myocardial infarction, heart failure, hypertension, dizziness, headache,
palpitation and breathlessness, etc.
Dosage and administration: Three times daily, 2 or 3 tablets each time after
meal, or prescribe by doctor.
Storage: Preserve in dried place in well-closed container. Guangzhou MingX-
ing Pharm. Fact.
Price: $2.40.
The package insert was in Chinese only, and there was no ingredient list in
English.
1614
17It is clear that the above prepackaged herbal medicines violate the provisions
of the DSHEA and the statutory provisions mandated by the Food, Drug and
Cosmetic Act for drugs. Many of these prepackaged Chinese herbal medicines
come without ingredient lists, and sometimes the information is in Chinese only.
The labels make fantastic claims about the diseases they treat, and it is di-
cult to believe that these brightly colored packages contain the treatments these
serious diseases and conditions. Yet they are readily available for purchase at
relatively low cost. These imported pre-packaged Chinese herbal medicines im-
ported mainly from China, Hong Kong, and Taiwan, with its farfetched labeling
and lack of ingredient lists, seem to be ripe for FDA regulation. In contrast,
domestically manufactured Chinese herbal medicines found in a general health
food store present a dierent picture entirely.77 The Chinese herbal medicines
manufactured in the U.S. make no health claims and list the ingredients. Hence
there is a stark contrast between Chinese herbal medicines manufactured in
the U.S. and compliant with DSHEA, and non-complaint imported medicines.
One disturbing fact regarding this disparity is that the non-compliant herbal
medicines are generally found in the Asian phannacies and stores, whereas gen-
eral health food stores catering to the mainstream public stock the compliant
domestically produced herbal medicines. This dierentiation in the distribu-
tion of unregulated imported herbal medicines then, produces a situation where
unregulated herbal medicines which are mislabeled and lacking in important
information are oating freely in the Asian communities in this country, height-
ening the risk of endangering Asian-American health and safety.
77Field research conducted at Cambridge Natural Foods, 1670 Massachusetts
Avenue, Cambridge. January 18, 1997.
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18B. Popularity of Traditional Chinese Herbal Medicine in the United States Today
Within the past two decades, Americans have begun to take a greater interest
in
traditional Chinese herbal medicine as well. An increasing number of con-
sumers seem to have become disenchanted by impersonal and beleaguered physi-
cians prescribing drugs
with strong side eects and so are turning to herbal teas, pills, extracts, and
salves for
78
help. Hence herbal teas, pills, and extracts can be found in drug stores for
the treatment
of all manner of ailments, and herbs are now the fastest growing category in
U.S.
drugstores.79 In a New England Journal of Medicine study, the total pro-
jected out-of-pocket expenses for unconventional medicine80 was $10.3 billion,
almost reaching the
level of out-of-pocket expenditures for all hospital care ($12.8 billion) and
almost half the total amount of out-of-pocket costs for all doctors' services
(about $23.5 billion.)8' The
same study found that in 1990 one out of three Americans had used an
alternative therapy
82
in the past year, herbal medicine being the most popular type employed.
This
tremendous growth has meant big business for herbal manufacturers and
dealers. In
83
1980, herbal product sales amounted to $167 million. It has skyrocketed
since then,
78Lauren Picker & Joshua McHugh, Herbal Medicine Goes Mainstream,
Am..LkaIth, May 1,
1996.
~ Smithsonian and ABC Sponsor Herbal Medicine Conference, Website of
the Smithsonian Institute, (1995).
80
Eisenberg denes unconventional medicine as medical practices that are not
in conformity
with the standards of the medical community. These include acupuncture,
chiropractic, massage therapy, herbal therapy, spiritual or religious healing by
others, commercial weight-loss
programs, lifestyle diets, energy healing, folk remedies, and megavitamin
therapy. David
Eisenberg, Unconventional Medicine in the United States{ Prevalence, Costs,
and Patterns of Use, 328 N~..Eng...LM~d. 246-252 (1993).
82~
83 Picker & McHugh, supra note 78.
1916
20with the U.S. herb industry having had an estimated $2 billion in sales in 1995,
and growing at an annual rate of about 20%.84
Surprisingly, according to the New England Journal of Medicine study, the
estimated number of visits to unconventional therapy practitioners outnum-
bered the
85
number of visits to primary care physicians. The majority of those who used
unconventional therapy did so to treat chronic, as opposed to life-threatening,
medical
86
conditions. About 1 in 4 Americans who see their physicians for a serious
medical
condition may be using unconventional therapy, yet 7 out of 10 times the
patient does not
87
inform the doctor of the use of unconventional therapy. Unconventional
therapies are
generally used in conjunction with conventional therapy, but about half of
those who use unconventional therapy for their principal medical conditions do
so without the supervision of a physician, a group estimated to number about
20 million Americans.88
Many doctors are coming to believe that alternative medicine is in some cases
a viable option as well. Wayne B. Jonas, director of the National Institutes of
Health's
Oce of Alternative Medicine, estimates that more than 50% of conventional
physicians
89
use or refer patients to alternative treatments. Although these studies do not
specically
focus on the prevalence of Chinese herbal medicine usage, they do indicate a
trend towards greater acceptance of alternative medicines in general. But they
also point to
84a
85 Eisenberg, supra note 80.
86~
88~
89 Marlene Cimons, New Life for Old Remedies; No Longer Dismissed as
Fringe Ideas, Such 'Traditional' Therapies as Acupuncture and Herbs Are Going
Mainstream, Los Angeles Times, Jan. 1, 1996.
17
21another danger: many people are using therapies without the oversight of a
medical practitioner, and doctors are treating their patients without obtaining a
complete medical history, a particularly hazardous situation because the doctors
may be prescribing medicines with conicting side eects and counterindications
with the herbal medicines.90
The doctors of tomorrow are being exposed early to traditional Chinese
medicine. Thirty-four of the 125 medical schools in the U.S. oer courses in
alternative medicine.9' At Case Western Reserve University School of Medicine
in Cleveland, medical students can enroll in Chinese Qigong I and I, while
students at the University of California at Los Angeles can go to its Center for
East-West Medicine, a clinic for traditional Chinese healing techniques to brush
up on their knowledge of Eastern therapies.92
Biotechnology rms and pharmaceutical companies have not been immune
to the growing interest in herbal medicines either, but such interest is not a new
phenomenon. For centuries, plant-based folk remedies have formed the basis
of Western medicine's pharmaceutical research.93 The discovery of Digitalis's
eectiveness in treating cardiac patients originated with a folk healer in Shrop-
shire, England in the late eighteenth century.94 However, with the appearance
of synthetic compounds in the 1950's, ethnobotany- the study of the relation-
ship between plants and people- faded as the leading source of pharmaceutical
leads.95 It is generally agreed that one quarter of
90 Eisenberg, supra note 80.
91 Pueng Vongs, TCM Going Primetime, Website of Channel A, Sept. 17, 1996.
92~
David Taylor, Herbal Medicine at a Crossroads, ~ Vol. 104, No. 9, Sept.
1996. 941d.
951d.
18
22Western medicines are derived from plants, although some believe the gure is
actually closer to 60%.96 Most Western plant-derived medicines, however, are
created by isolating active ingredients, and not from the complex set of com-
pounds that is found in most herbal remedies.97 Recently, however, ethnobotany
has reappeared, and scientists
trained to perform eld work and bioassays made possible by technological
advances can
98
now test compounds against a wide array of diseases. These developments
have
sparked investment in biodiversity prospecting, a wider approach than eth-
nobotany that carries out broad inventories of species in diverse ecosystems.99
Within the realm of established Chinese medicines, however, the pharmaceutical
company Pharmagenesis Inc., is developing new pharmaceuticals based on leads
from traditional Chinese medicines.100 And Pzer Inc., under an agreement with
the China Academy of
Traditional Medicine in Beijing, is also studying traditional Chinese herbs
to nd
101
potential sources of new medicines.
There are two basic approaches to drug discovery: rational drug design and
102
conventional random screening. Rational design-engineering new drug molecules
requires knowledge of the drug target (like a receptor or enzyme), which
although
103
promising, has had limited payos. With random screening, synthetic chem-
icals or
96~
971d.
98~
9914k
lao
Alison Mack, Biotechnology Turns to Ancient Remedies in Quest for Sources
of New
Therapies, ~ Jan. 6, 1997 at 1, 8.
101
102
Tianhan Xue, Exploring Chinese Herbal Medicine Can Foster Discovery of
Better Drugs,
Ih~..S.~knIjst, Vol. 10, #4, Feb. 19, 1996, at 9.
103
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23natural products are indiscriminately tested for biological activity, which can be
costly and time consuming.'~ Proponents of research into traditional Chinese
medicine believe that in the area of drug discovery, developing new drugs based
on leads from Chinese herbs is more eective than the conventional method of
random screening because of the long history of clinical practice in Asia.'05 The
Chinese ethnopharmacopoeia has been
written down and is still taught in medical schools in China today, making
it a living and
106
vibrant system. In China, where almost 7,300 plants are used in Chinese
herbal
medicine, about 60 new herb-derived drugs have been developed by Chinese
scientists
107
over the last four decades. Champions of investigating Chinese herbs for modern
medical use point to cases where Chinese herbal therapies were eective
when Western
108
therapies were not. In a double-blind British clinical trial, a formula of Chinese
herbs
produced signicant results in cases of severe atopic eczema, which was pre-
viously
109
resistant to conventional therapy. A controlled clinical trial in Japan showed
that shosaiko-to, an extract of seven Chinese herbs, helps prevent liver cancer
in patients with cirrhosis, marking the rst treatment from any medical system
that oers such benets.0 In the U.S., several drugs of Chinese-herb origin are
being commercially developed, including antimalarial drug qinghaosu deriva-
tives'; huperzine A, for Alzheimer's disease and trichosanthin, which combats
HIV and has completed Phase II
105 Tianhan Xue, Traditional Remedies, Modern Medicine, Th~..S.~knIist,
Vol. 10, #2, Jan. 22,
1996, at 12.
'~Mack,supranote 100, at 1.
107 Xue, supra note 102, at 9.
108 Xue, supra note 105, at 12.
109
M.P. Sheehan & D.J. Atherton, British Journal of Dermatology, 126:179-84,
(1992). CiI~din Xue,supranote 105, at 12.
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24112
clinical trials. A 1994 study published by the Oce of Alternative Medicine
cites more than nine published scientic studies, conducted mostly in Europe,
conrming ginkgo's eectiveness in improving cognitive function and circulation
and in reducing the risk of cardiovascular disease.3 The study also cites studies
conrming benets of milk thistle (Silybum marianum, used to prevent and re-
pair liver damage) and saw palmetto (Serenoa repens, eective against benign
prostatic hypertrophy).4 In 1990, a research team led by Sylvia Lee-Huang of
New York University School of Medicine, Hao-Chia Chen at the National Insti-
tutes of Health, and Hsiang-fu Kung at the National Cancer Institute isolated
a protein, MAP 30, from bitter melon, which has been used in China to treat
infections, tumors, and immune disorders, and found it has multiple functions
that are responsible for anti-HIV activity. ~ These ndings prompted William
Paul, the director of AIDS research at NIH, to comment that the development
must be vigorously pursued.6
The staunchest opponents of Chinese herbal medicine and other forms of
alternative therapy claim that the increased prominence of alternative thera-
pies is anti-science and part of a growing tide of irrationalism in the U.S. and
Europe.117 They claim that the untestable belief systems upon which alternative
therapies such as Chinese herbal
110 H. Oka et al., Can~r, 76:743-9, (1995). CiI~din Xue, su~ra note
102, at 9. D.L. Klayman, ~ 228:1049-55, (1985). Cit~din Xue, supra note 102,
at 9.
112
S. Bornian, Chemical and Engineering News, Sept. 20, 1993, at 35-6. $it~din
Xue, supra
note 102, at 9..
113 Taylor, supra note 93.
114 Id.
115
S. Lee Huang et al., Proceedings of the National Academy of Sciences, 92:8818-
22, (1995). C.it~d.inXue,supranote 102, at 9.
116
W. Paul, ~gkng&, 267:633-6, (1995). ~iI~in Xue, supra note 102, at 9.
117 Franklin Hoke, Scientists See Broad Attack Against Research and Reason,
Ib&.S~knUsi,
Vol. 9, #14, July 10, 1995, at 1.
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25118 Id.
medicines are based attacks scientic inquiry by diverting public support for
118
experimental research. Others who are less extremist contend there are seri-
ous concerns to be addressed regarding the safety of Chinese herbal medicines.
Continued
research and development of new drugs from Chinese herbal medicines may
be the best way of silencing such criticism. But in order to present pure com-
pounds with demonstrable eects backed by clinical studies, one must rst iso-
late the hundreds of compounds found in a single Chinese herbal remedy, which
if not impossible, will take a very long time. In the meantime, people will still
use unregulated Chinese herbal medicine, as the recent surge in its popularity
has demonstrated. The dangers of imported medicine are greater because they
do not conform to any FDA standards, while the U.S. produced herbal medicines
are more careful about avoiding health claims and listing ingredients. But this
does not mean that they can be assumed safe either. Because the domestically
produced products do not make health claims, consumers tend to depend on
store clerks for information about the dierent medicines, and the clerks may
not be well-informed, let alone experts, about the uses of the dierent herbal
products. Moreover, for manufacturers who wish to avoid the pre-approval pro-
cess for drugs, marketing as a dietary supplement provides an attractive way
to get their product on the market quickly, although the compound may still
technically be a drug.
C. Dangers of Traditional Chinese Herbal Medicine
The increasing popularity of traditional Chinese medicines in the U.S. has
caused a rise in the importation of potentially dangerous herbal medicines,
mainly from Asia, but
22
26domestically manufactured Chinese herbal medicine pose dangers as well.9 Var-
ious factors can contribute to the dangerous use of Chinese herbal medicines.
First, there are numerous dierent herbs that can be mixed in dierent combi-
nations, so there is a sizable
120
margin of error. Second, the labeling on prepackaged herbs does not always
reect
the contents nor do they provide appropriate directions and wamings about
side eects or
121
counterindications. Those who use alternative medicine along with conventional
treatments may be harming themselves when the doctor is unaware of that
fact and/or
122
there is little known about the interaction between the medicines. And when
directions
and warnings are provided, they are often written only in Chinese with
imported
123
medicines. Moreover, because imported products come from dierent places,
the
124
products are not necessarily uniform in quality or manufacturing. Foreign
pharmaceutical companies often do not use rigid quality control standards
nor do they test
125
their products for purity or reliability. So the risk of contamination with toxic
contaminants is a source of great concern. Herbal preparations can be di-
rectly toxic or toxic when taken in combination with other preparations.126
Metals poisoning has been found on numerous occasions with Chinese herbal
medicines. Recently, a chemist in the FDA's Seattle oce analyzed a popular
Chinese medicine known as rhino horn tea balls,
119 Evelyn Iritani, A Warning on Imported Herbal Medicine Lethal Toxins
Found in Some Formulas, Seattle Post-Intelligencer, Nov. 9, 1994.
120
Elaine Kang-Yum, Cross-Cultural Miscommunication, The Hastings Center Report,
Vol.
26, No. 3, May 15, 1996.
121
122 Rick Weiss, A Closer Look at Herbal Remedies; Federal Ocials Exam-
ine Anecdotal Evidence on Safety, Usefulness, The Washington Post, Dec. 20,
1994.
27123 Kang-Yum, supra note 120.
124
125 Jacqueline Gazzella & John Pinto, Herbs: Use and Abuse, Current Concepts and Perspectives in Nutrition,
Vol. 6, July 1987.
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28which was supposedly made up of herbs and ground rhino horn and used to
treat people
127
who had high fevers or had suered a stroke. The chemist discovered
that the
128
medicine contained dangerously high levels of arsenic, lead, and mercury.
Cases of lead poisoning caused by the ingestion of certain herbal products have
been reported in
China, however, it was unclear whether the lead was an ingredient or a
contaminant.'29 High levels of toxicity were also linked with use of Jin Bu Huan,
a traditional Chinese
130
herbal product used as a sedative and analgesic. A 1994 Joumal of the American
Medical Association article reported that three Colorado children who had
taken Jin Bu Huan manifested life-threatening central nervous system and res-
piratory depression.'3'
Subsequently, three women in Los Angeles were diagnosed with acute hep-
atitis attributed
132
to the use of Jin Bu Huan. The JAMA report concluded that Jin Bu Huan or
one of its
components was hepatotoxic. '~ Other imported Chinese herbal medicines
have been found to contain various Western medicines, including barbiturates,
nonsteriodal anti-inammatory agents, antibiotics, diuretics, and narcotic pain
relievers.'34 Proponents of Chinese herbal medicine maintain that small amounts
of toxic metals such as lead and arsenic are used now and then to treat specic
medical problems, and only for short
126 Id.
127
Iritani, supra note 119. The rhino horn tea ball product was conscated
because it allegedly
contained endangered animal components. Id.
128 Id.
129
130
G.M. Woolf et al., Jin Bu Huan Toxicity in Adults- Los Angeles, 1993, 271
JAMA 423
(1994).
131
132 Id.
133
134 Kang-Yum, supra note 120.
2924
30periods of time.'~ The danger, they argue, stems from people self-medicating
and
ingesting toxic levels of these substances, or from taking products that are
improperly
136
mixed or mislabeled. Herbs, like drugs, they contend, should be approached
with
caution, but given a chance to work.'37
The problem of misidentication is another related major source of concern,
i.e., when by accident or through deliberate fraud, the plant product described
on the label is dierent from that in the pill, capsule, or tincture.'38 The absence
of an international agreement for common or Latin botanical names exacerbates
matters. '~ An analysis of
24 herbal preparations of ginseng revealed the absence of ginsenosides, the
active
140
pharmacological constituent in ginseng. Instead, the ginseng preparations con-
tained
incorrect species, altered mixtures of species, underweight products, and
improper product labeling.'4'
Chinese herbal medicine claims its ecacy lies in the complex interaction be-
tween the various chemicals in the medicine, which can number in the thousands.'42
Therefore it is dicult if not impossible to isolate pure ingredients and to ob-
tain the reproducible results the FDA requires before approving a drug for even
investigational status and testing.'43 Part of the diculties in testing and main-
taining purity arises from
135 Iritani, supra note 119.
136
137
138 Weiss, supra note 122.
139
140 Gazzella & Pinto, ~pra note 125.
141 Id.
142
Arielle Emmett, Where East Does Not Meet West, Technology Review, Vol.
95, No. 8, at
50, 53 (1992).
143
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31the use of whole herbs rather than individually isolated active ingredients.' But
supporters of Chinese herbal medicines assert that pure chemicals are not as
eective as whole herbs.'45 And there is also a possibility that individual ac-
tive compounds may cause undesirable side eects without balancing chemicals
present in traditional treatments. 146
III. Regulation of Traditional Chinese Herbal Medicine Under Current Laws
There are currently no regulations designed specically for herbal medica-
tions in the United States. Under current FDA procedure, herbal medications
may fall within the following regulatory categories: as foods, food additives,
dietary supplements, or drugs. However, herbal medications generally come un-
der the provisions for nutritional supplements because it is dicult for herbal
medications to meet the FDA's sti drug standards and they do not conform
exactly to the denitions of food or food additives.147
A. History of Food and Drug Regulation in the U.S.: An Overview
America inherited a tradition of food regulation from England manifested in
state laws as well as in federal laws promulgated with an aim towards regulating
specic foods.'48 In 1906 Congress enacted the Food and Drugs Act, the rst
federal statute to expansively prohibit the misbranding and adulteration of food.
Though the 1906 Act
~Mack, supra note 100, at 1.
I.d.
146
147 Edgar R. Cataxinos, Note, Regulation of Herbal Medications in the
United States: Germany
Provides a Model for Reform, Utah Law Review 561 (1995).
148 Peter Barton Hutt, Government Regulation of the Integrity of the Food
Supply, 4..Annua,1
Review of Nutrition 1 (1984); ~aJ~ Peter Barton Hutt and Richard A. Mer-
rill, E~daIJ~rug
Law: Cases and Materials (2d ed. 1991), at 1-4.
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32provided some protection against fraud, it had serious limitations, among
them a lack of legal standards for foods, of restrictions on the use of poisons in
drugs, and of fraudulent statements regarding drugs that are not in or on the
food or drug package.149 A tragedy in 1937 in which at least 73 people died as
a result of taking the drug known as elixir
sulfanilamide opened many people's eyes and prompted Congressional ac-
tion. The only legal basis for FDA intervention in that case was the fact that
the preparation was
misbranded, since it was not a proper elixir.'50 To remedy these shortcom-
ings, Congress passed the Food, Drug, and Cosmetic Act of 1938 (FDCA), which
has been amended
many times since and currently regulates food and drugs.
Section 505 of the 1938 FDCA Act authorized the FDA to permit new drug
applications (NDAs). Another tragedy, this time involving deformities in babies
of
women who took thalidomide during their pregnancies, prompted Congress
to act again. Congress responded by passing the Drug Amendments of 1962,
which required the FDA to armatively determine that new agents have been
demonstrated by substantial
152
evidence to be eective, in addition to being safe. The eect of the 1962
Amendments was to hoist the onus of proving pre-market ecacy and safety
onto the shoulders of the drug manufacturers.
B. Possible Classications of Chinese Herbal Medicine
149 1917 Report of the USDA Bureau of Chemistry (1917); ~ Hutt and Mer-
rill, supra note
148, at 11.
ISO David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Leg-
islative History and Its
Substantive Provisions, 6 Law & Contemporary Problems 2 (1939); s~..alsu
Hutt and Merrill, supra note 148, at 476.
1933 Report of the Food and Drug Administration (1933); ~ Hutt and Mer-
rill, supra note 148, at 11-13.
152 Hutt and Merrill, supra note 148, at 478.
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33Currently, there is no FDA denition for herbal medication, so regulation of
traditional Chinese medicine may fall into one of the following four categories,
depending on the use to which the product is put:
1. E~d~
The term food is dened as a) articles used for food or drink for man or
other animals, b) chewing gum, and c) articles used for components of any
such article.'53 Herbal medicine could be classied under a) or c). Under a
food classication, the government bears the burden of proving the food is
dangerous to the public health.'54 But there are other ways to reach the herbal
manufacturer for a product that is classied a food: the FDA can challenge
an herbal manufacturer for the introduction or delivery for introduction into
interstate commerce of any food...that is adulterated or misbranded.'55 A food
is deemed adulterated if it contains any poisonous or deleterious substance which
may render it injurious to health.156 The FDA can then instigate a seizure of
the herbal medicine and prosecute the manufacturer if health problems arise
from its use.157 A food
is misbranded if its label is false or misleading, and the extent to which the
labeling fails
~58
to reveal facts material to representations made is also taken into account.
Again, this is grounds for the FDA to seize the product and prosecute.159
2. E~d.Ad4iiiy~
~ 21 U.S.C. x 321 (f).
154 United States v. An Article of Food, 678 F.2d 735, 739 (7th Cir.1982).
'~~21 U.S.C. x 331 (a).
156 21 U.S.C. x 342 (a)(1).
'~' 21 U.S.C. x 342 (a)(l), x 333 (a), x 334 (a) (1).
15821 U.S.C. x 343 (a)(1), x 321 (n)..
159 21 U.S.C. x 334 (a).
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34Food additive is dened as any substance whose intended use results in or rea-
sonably can be expected to result in its becoming a component of or otherwise
aecting any food.'60 A food that has a food additive not found safe by the
FDA or which has an approved additive in excess of the approved quantity is
deemed adulterated,
and any additive in either of these categories is presumptively unsafe until
it receives
161
FDA approval. The approval process requires the ling of a premarket pe-
tition, so the
manufacturer basically bears the burden of proving safety.'62
The seemingly expansive language of the food additive denition is circum-
scribed by certain exceptions, including the following pertinent categories of
substances: a) those that are generally recognized as safe; b) those that have
been used in a substance before January 1, 1958, and has been found to be safe
through either scientic procedures or experience based on common use in food;
c) any substance used in accordance with a sanction or approval granted prior to
September 6, 1958, the Poultry Products Inspection Act or the Meat Inspection
Act of March 4, 1907; or d) an ingredient meant for use in or intended for use
in a dietary supplement.'63
For herbal manufacturers, it is important that their products fall outside the
scope of the food additive denition, which requires undergoing costly testing
and premarket approval procedures. Exception d), which was amended with
the passage of the Dietary Supplement Health and Education Act of 1994, is
the one most herbal manufacturers now
16021 U.S.C. x 321 (s).
161
21 U.S.C. x 342 (a) (2) (C), 348 (c) (1) (A).
362 21 U.S.C. x 348 (b), (c).
163
21 U.S.C. x 321 (s). There are other exceptions for pesticides, color additives,
and animal
drugs. Id.
29
35use to escape the strictures of the food additive denition.IM But they still
remain subject to other food safety provisions.
3.Dn~g~
A drug is dened as a) articles recognized in the United States Pharma-
copoeia, Homeopathic Pharmacopoeia, or National Formulary; b) articles in-
tended for use in the diagnosis, cure, mitigation, treatment, or prevention of
disease in man or other animals; c) articles (other than food) intended to aect
the structure or function of the body (human
or animal); or d) articles intended for use as a component of any article
specied in a), b),
165
or c) above. In determining the intended use of a product for use as a drug,
the FDA
considers representations made by the manufacturer in any forum, not just
statements on the package label or insert.'66 The FDA has a number of times
employed the broad denition of drug to regulate products that would have
otherwise been subject to the food, device, or cosmetic provisions, in order to
mandate premarket testing and approval,
167
as required for all new drugs. The Supreme Court has upheld the FDA's
authority to
168
do so in order to accomplish its broad public health aims. Since the require-
ments for
The Ninth Circuit also limited the use of the food additive classication un-
der exception b) for a Chinese herbal product which contained schizandra seed,
traditionally used in China but which had not been a tested, commonly used
food additive in the U.S. before 1958. The court in Fmali Herb. Inc. v. Heckler
found that the common use language did not exclude evidence of the product's
use outside the U.S. as probative of a food's safety, thereby limiting the FDA's
regulation of traditional Chinese herbal products as a food additive. 715 F.2d
1385 (9th Cir. 1983).
165 21 U.S.C. x 321 (g) (1).
166
Hutt and Merrill, supra note 148, at 386. Hutt and Merrill note that in an
FDA regulatory letter regarding Favor Smokeless Cigarettes, the agency made
use of company statements to the SEC. Id.
Id. at 385.
168
Id. In United States v. An Article of Drug...Bacto-Unidisk, the Supreme
Court found that the 'natural way' to draw the line 'is in light of the statutory
purpose.' Since the patient will tend to derive less benet and perhaps some
harm from a particular antibiotic if, though the drug
30
36drugs are generally stricter than those for foods or dietary supplements, manu-
facturers do not want their products to fall into this category.
a. Drug Approval Process
A drug can travel up the drug approval process through two channels. The
rst
path is if it is exempt by the grandfather clauses in either the FDCA or the
1962
169
Amendment. If the drug can not be exempted through a grandfather clause,
then the
manufacturer must go through the new drug approval process. Evaluating
safety and eectiveness, and risk vs. benet are the pivotal issues in FDA drug
review. But it is a long and costly process, taking about 7 to 13 years and
$30-$50 million to take a drug
170
from research to marketing approval. There are three major stages, the rst
one being
precliical research to identify whether the drug is suciently promising to
study in
itself was properly batch-tested, it was not the proper antibiotic to use, it
was entirely reasonable for the Secretary to determine that the discs, like the
antibiotics they serve, are drugs and similarly subject to pre-clearance certica-
tion under x 507. An opposite conclusion might undercut the value of testing the
antibiotics themselves, for such testing would be a useless exercise if the wrong
disc were ultimately administered, even partially as the result of an unreliable
disc... 394 U.S. 784 (1969).
269
21 U.S.C. x 321 (p) (I). Under the FDCA, a drug shall not be deemed to be
a 'new drug' if
at any time prior to the enactment of this chapter it was subject to the Food
and Drugs Act of June 30, 1906, as amended, and if at such time its labeling
contained the same representations concerning the conditions of its use... Id. ~
Pub. L. No. 87-781, x 107 (c) (4), 76 Stat. 780, 789 (1962). Under the 1962
Amendments, a drug which (A) was commercially used or sold in the United
States, (B) was not a new drug as dened by section [321(p)] of the basic Act as
then in force, and (C) was not covered by an eective application under section
[355] of that Act, ... when intended solely for use under conditions prescribed,
recommended, or suggested in labeling with respect to such drug. Id.
170
Report of the Subcommittee on Science, Research and Technology of the
House Committee on Science and Technology, The Food and Drug Adminis-
tration's Process for Approving New Drugs, 96th Congress, 2d Session (1980).
Cited in Hutt and Merrill, supra note 148, at 514-516. The exact length of the
37drug review can vary since the FDA classies investigational new drug appli-
cations (INDs) and new drug applications (NDAs) and assigns review priority
based on the drug's chemical type and potential benet. FDA Drug Approvals
List, Website of the
FDA (1997).
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38171
humans, which takes from 1 to 4 years. If the drug passes the rst stage,
the
manufacturer les for an Investigational New Drug application (IND). If the
FDA does not reject the lND, the manufacturer can begin the second stage,
which consists of three
phases of clinical research designed to determine eectiveness in humans and
to
172
investigate side eects, which usually takes 4 to 6 years. In phase I the drug
is
administered to humans with the primary purpose of detecting adverse ef-
fects and usually does not provide data on the ecacy of the drug on the disease
it is meant to treat. '~ If
the adverse eects do not so limit, the drug passes to phase II studies, which
studies the
drug in patients with the disease it is designed to treat.174 The objectives
are to determine whether the drug has the desired therapeutic eect and if so at
what dosage, and whether there are adverse eects.175 If the drug is considered
safe and eective, it passes into
phase III for more clinical study. In phase III, many more patients are
studied, usually in
176
a clinical environment. The clinical, pharmacological and toxicological data
for a drug
that passes at least two phase III trials is then collected in a New Drug
Application (NDA) and submitted to the FDA Bureau of Drugs.'77
The information required in an NDA includes the results of the clinical tests;
the drug's constitution{its components and composition; results of the animal
studies; and
171 Id.
172
173 Id.
174
175
176 Id.
177
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39how the drug functions in the body.'78 Documentation addressing how the
drug is
manufactured, processed and packaged, particularly the quality controls em-
ployed, are
179 180
also obligatory. Samples of the drug and its labels are necessary as well.
Eectiveness is then determined, especially on the basis of the controlled
clinical trials, but the whole data bank is used to search for adverse eects.'8'
FDA reviewers then
evaluate the risk versus benet of the drug.
Field inspectors are sent to make on-site checks of the investigators who
performed the studies to ensure its validity, and since more foreign studies
are being
accepted as evidence for drug approval, the FDA has been doing more foreign
182
inspections. If the FDA nds major discrepancies between their survey and
the drug
sponsor's, more data may be required before approval can be granted. Drug
review for a single product is a time consuming process, in recent years averaging
about two years to complete.'83
For many traditional Chinese herbal manufacturers, the time and money
needed to complete the new drug approval process is prohibitive. Moreover, the
lack of patent
protection for plant-derived products acts as a monumental disincentive to
undertaking
184
the costly drug review process.
b. Over-the-Counter Drugs
178
Dixie Farley, Benet vs. Risk: How FDA Approves New Drugs, EDA~Qnsum~r,
January
1995.
179 Id.
180 Id.
181
182
183 d.
184 Cataxinos, supra note 147, at 574.
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40The 1962 Drug Amendments compelled the FDA to review all Over-the-
Counter
185
(OTC) drugs. To deal with an estimated 100,000 to one-half million OTC
drugs, the
l86
FDA initiated rulemaking by therapeutic classes on an industry basis. This
was done
through the implementation of monographs which established conditions
under which a
category of OTC drugs were generally recognized as safe and eective and
not
187
misbranded. Any drug which had not received NDA approval or OTC mono-
graph
l88
status could then be seized as an unapproved new drug. Consideration of
homeopathic
drugs was explicitly deferred because they represented such a small volume
of OTC
189
products. However, traditional Chinese herbal medicine was not likewise
exempted,
simply because it did not occur to the authors of the OTC monograph system
to address the practice. I 90
One major obstacle for Chinese herbal medicines may be due to the com-
plexity of its chemical compositions. To qualify for OTC monograph status, the
drug is evaluated
as a whole, and the individual constituents do not need to be identied for
purposes of determining safety and eectiveness.'9' But the FDA's OTC panels
consist of experts
192
who evaluate specic chemical compounds within that OTC category. The
complex
185 Hutt and Merrill, supra note 148, at 588.
186 Over-the-Counter Drugs: Proposal Establishing Rule Making Procedures
for Classication,
37 Federal Register 85 (January 5, 1972); ~iL~din Hutt and Merrill, supra note
148, at 589.
187 Over-the-Counter Human Drugs Which Are Generally Recognized as Safe
and Eective and
not Misbranded, 21 C.F.R. Part 330 x 330.10; Cit~din Hutt and Merrill, supra
note 148, at 595.
188 Hutt and Merrill, supra note 148, at 590.
189 ~ Fed. Reg. 9464, 9466 (May 11, 1972); ~iI~d.in Hutt and Merrill, supra
note 148 at 596
41(1991).
'~Conversation with Peter Barton Hutt, January 6, 1997.
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42make-up of herbal medicines, which often have dozens of active ingredients,
make it dicult even to identify the dierent compounds in Chinese herbal
medicines. So although OTC review technically permits multiple compound
drugs, the inability to identify the active chemical constituents in herbal medicines
makes securing approval under the safe and eective standard generally unattain-
able.
Nonetheless, when Chinese herbal medicines are clearly labeled to prevent
or treat disease, thereby making drug claims covered by the OTC monographs,
the FDA has signaled its intention to challenge such products, even if they claim
to be dietary
193
supplements. For example, the FDA recently issued a warning letter to a
company
whose energy boosting product contained the Chinese herbs ginseng, ma-
huang, and guarana.'94 The FDA alleged that the manufacturer was making
unlawful drug claims because the product's claims fell under the Stimulant
Drug Products OTC Drug Monograph. '~ Commentators have argued that the
DHEA creates a new regulatory scheme for dietary supplement products, and
so if an OTC drug monograph has been established for an indication that is
also a permissible dietary supplement statement under
section six of DSHEA, the monograph should be applicable only to products
that do not
196
meet the denition of a dietary supplement. Since DSHEA does not qualify the
range
of statements that can be made by dietary supplements with any mention
of potential
~ Robert Pinco & Paul D. Rubin, Ambiguities of the Dietary Supplement
Health and
Education Act of 1994, 51 $~Qd..&Drug..LJ~ 383 (1996), at 392.
194 Id.
195 Id.
196a
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43conicts with the OTC drug review, certain OTC monographs may no longer
be applicable to dietary supplements.'97
4. Dietary Supplements
The ndings section of the 1994 Dietary Supplement and Health Educa-
tion Act recognized that 50% of 260 million Americans regularly consume di-
etary supplements of vitamins, minerals, or herbs in an eort to improve their
nutrition.'98 The passage of the Dietary Supplement Health and Education Act
of 1994 (DHSEA) has generally been heralded as a positive development for
dietary supplement manufacturers and consumers. '~ Under DSHEA, a dietary
supplement is dened as a product (other than tobacco) that is intended to
supplement the diet and contains one or more of the following dietary ingredi-
ents: a vitamin; mineral; herb or other botanical; amino acid; dietary substance
to increase total dietary intake; a concentrate, metabolite, constituent, extract,
or combination of any of the aforementioned ingredients.200 It must also be in
a traditional supplement dosage form, i.e. tablet, capsule, softgel, powder or
liquid, or if not in such a form, it has to be labeled as a dietary supplement and
it must not be represented for use as a conventional food or as a replacement
for a meal or total diet.20'
The eect of this expanded denition is to ensure that the new protections
of the DSHEA is applicable to a wide array of products, including those that
the FDA deems as
297 Id.
198
21 U.S.C. x 321 (9) (1994) (new section 201(9) of the FDCA).
199
Stephen H. McNamara, Dietary Supplements of Botanicals and Other Sub-
stances: A New Era of Regulation, 50 Food and Drug Law Journal 341 (1995).
200 Pub. L. No. 103-417 x 3 (a), 108 Stat. 4327 (1994).
201
Id. ~ Covington & Burling Memo, Dietary Supplement Health and Educa-
tion Act of 1994, (October 12, 1994).
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having no nutritional value. Another important eect of the new law is the
explicit amendment of the FDCA to prevent the application of the food additive
category to dietary ingredients or supplements. Before, the FDA had argued
that substances added to dietary supplements were like substances added to any
food product. If the substance
was not generally recognized as safe by experts, it was considered subject to
regulation
203
as a food additive. Filing a food additive petition required research and could
cost
upwards of $1,000,000 and usually took over ve years before the FDA
approved.2 ~This meant that dietary supplements that contained ingredients that
were viewed as food additives were illegal. DSHEA changes this frightening
prospect for herbal drug manufacturers by preventing the term food additive
from being used to regulate dietary supplements and their ingredients.
Under DSHEA, a dietary supplement is considered adulterated if it poses a
signicant or unreasonable risk of illness or injury, or an imminent hazard to
public health or safety.205 The FDA has the burden of proving each element of
adulteration.206 Another concession to dietary supplements made by DSHEA
is with regard to health claims. Under the Nutrition Labeling and Education
Act (NLEA), manufacturers were forbidden to print health claims on any food
products, including dietary supplements,
202
McNamara, supra note 199, at 342. The new denition also allows an article
which has been marketed as a dietary supplement or a food before it has been
approved as a drug, certied as an antibiotic, or licensed as a biologic by the
FDA, to continue to be marketed as a dietary supplement unless the FDA
publishes a regulation forbidding it. Id.
Id.at343.
204~
205
Pub. L. No. 103-417 x 4 (f), 108 Stat. 4327 (1994).
206
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45207
without FDA approval. DHSEA devised an exception to this by allowing cer-
tain statements to be made by a dietary supplement if the statement: a) claims
a benet related to a classical nutrient deciency disease; b) describes the role
of a nutrient or dietary ingredient intended to aect the structure or function
in humans; c) characterizes the documented mechanism by which a nutrient or
dietary ingredient acts to maintain such structure or function; or d) describes
general well-being from consumption of a nutrient or dietary ingredient.208 The
manufacturer has to substantiate that the statement is truthful and not mis-
leading and the statement has to include the following text: This statement
has not been evaluated by the Food and Drug Administration. This product is
not intended to diagnose, treat, cure or prevent any disease.2 ~The manufacturer
then
has to notify the FDA no later than 30 days after the rst marketing of the
dietary
210
supplement that such a statement is being made. The FDA has the burden of
showing
that the dietary supplements are unsafe.21'
The previous dividing line between drugs and dietary supplements was col-
lapsed somewhat with Congressional passage of the DSHEA. Section six of
DSHEA allows dietary supplement product labeling to include statements of
nutritional support, however, the FDA still has premarket approval of certain
drug claims. So if the supplement makes drug claims, or consists of a sub-
stance already regulated as a drug, then it will fall subject to the statutory
requirements for drugs, which the dietary
207 McNamara, su~ra note 199, at 345.
208 FDCA x 343 (r) (6).
209 Id.
210
211
FDA Panel Urges Controls for Herbal Ephedrine Products, W~iiL~.gaJ 1,
9-5-96 WLN
9241, September 5, 1996.
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46supplement industry wants to avoid. The denition of drug includes articles
intended for use in the diagnosis, cure, mitigation, treatment or prevention of
disease in man or other animals and articles (other than food) intended to aect
the structure or any function of the body of man or other animals.222 Therefore,
if a dietary supplement manufacturer makes a claim that a dietary supplement
diagnoses, cures, mitigates, treats or prevents disease, the dietary supplement
will be subject to the premarket approval process of a drug. But the second
clause, classifying articles that make structure or function statements as drugs,
should no longer apply to dietary supplements because
DSHEA permits truthful structure and function statements, and states that
dietary
213
supplements are foods and not drugs. An unresolved issue is whether some
dietary
supplement claims authorized by section six will fall under the drug denition.224
For example, if there is a product that claims to improve joint exibility, can
the FDA
215
regulate it as a drug claiming to treat arthritis. Commentators have argued
that based
on congressional intent and the statutory language of DHEA, the FDA
should not characterize such legitimate structure/function claims and general
well being claims as
216
drugs. They argue that DSHEA was designed to encourage the dissemination
of
truthful dietary supplement information to consumers without having to
wait for FDA
212 21 U.S.C. s. 321(g)(1).
213 Pub.L. No. 103-417,s 10, 108 Stat. at 4331 (codied at2l U.S.C. s 321(g)(l)).
224 Pinco & Rubin, supra note 193, at 390.
215
216
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47pre-approval.227 Thus, if the reach of the FDA extends to implied claims, there
is no limit to the FDA's control, because any claim will have an ostensible link
to disease.218
IV. Responses to Traditional Chinese Herbal Medicine
A. State and Federal Responses
The FDA has yet to contend specically with the regulation of Chinese herbal
medicine, but other government agencies and state legislatures have taken no-
tice. The Oce of Alternative Medicine (OAM) was created within the auspices
of the National Institutes of Health to investigate an array of alternative treat-
ments, including Chinese
219
herbs. Almost $8 million in funds earmarked by Congress for this purpose
is being
apportioned to eight research centers over three years, which began in 1994.220
At the
University of Texas, research on biopharmacologic remedies is currently un-
derway to test
221
the eects of herbs and natural products on cancers. It is hoped that some
of the
alternative techniques, if validated through clinical trials, will join main-
stream
222
medicine. Wayne Jonas, director of the OAM, points out that It's always
been true
that the 'mainstream' of today is the 'alternative' of the past.223 Out of the
40 research
217 Id..
228
219 Joy Mcintyre, OAM Commences $8 Million Investigation into Alternative
Therapies, Ih~
S~i~nti~I, Vol. 10, #2, at 3 (1996).
220
222
222 ~d.
223 Id..
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48projects funded by the OAM between 1993 to 1995, ve dealt with Chinese
herbal medicine.224
Federal legislation is currently being considered that may ease the accep-
tance of non-traditional therapies like Chinese herbal medicine by respecting
individual's choices regarding treatment. The Access to Medical Treatment
Act, proposed in July 1995 by Senator Tom Daschie, would allow an individual
to choose any medical treatment oered by a health care practitioner, including
medical care that has not been approved, certied,
or licensed by the Secretary of Health and Human Services, as long as the
patient is
225
informed of the approval status. Though the Access to Medical Treatment
Act has not
yet been enacted, the Department of Health and Human Services has estab-
lished a set of
226
regulations concerning Emergency Access to Promising Therapies. This ap-
plies only
to individuals who are in a life-threatening situation and unable to give their
consent,
227
however. Several conditions must be met rst: available treatment must be
unproven
or unsatisfactory; the risks and benets of the experimental procedure have
to be reasonable in light of the patient's medical condition and standard therapy;
and the
228
research into the experimental therapy can not be carried out otherwise.
This set of
regulations was made possible by the FDA's issuance of nal rules making
it easier for promising experimental drugs and medical devices to be studied in
those who are in life-
224 Corinna Wu, Yin and Yang, Western Science Makes Room for Chinese
Herbal Medicine, ~ Sept. 9, 1995, at 172.
225 ~ 1035, 104th Cong., 2d Sess. (1995).
226 Don McLearn, HHS Regulations Provide Emergency Access to Promis-
ing Therapies,
Website of the FDA, P96-16 (Sept. 26, 1996).
227 Id.
228
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49threatening situations and unable to give informed consent, and an NIH
publication of an
229
Emergency Research Consent Waiver applicable to all agencies of the HHS.
These new policies were adopted in response to growing uneasiness that current
regulations
were making research in emergency circumstances dicult at a time when
such research
230
was desperately needed. The willingness to accept non-traditional treat-
ments in
emergency situations as demonstrated by these regulations opens the window
for greater research into alternative therapies like Chinese herbal medicine.
Various states have also developed their own responses to the use of alter-
native
therapies generally and Chinese herbal medicine in particular. New York
State amended its education and public health laws, so that of the eighteen
physicians on the board for
professional medical conduct, now at least two are physicians who dedicate
a signicant
231
portion of their practice to non-conventional medical treatments. Most im-
portantly for
consumers, Chinese traditional medicine is also making its way onto the
list of covered treatments under an increasing number of health maintenance
organization plans.
Washington state now requires every health insurer to cover alternative treat-
ments like acupuncture, massage therapy, naturopathy, and other forms of li-
censed natural health
232
care. HMO's like Kaiser Permanente and insurers like Prudential are already
covering
233
acupuncture. It is estimated that by 1998, 25% of all managed care programs
will
229 Id.
230
231 N.Y. Public Health Law x 230 (McKinney's 1994).
232 Timothy Egan, Seattle Area Giving Natural Medicine a Chance to Come in
from the Fringe, The New York Times, Jan. 3, 1996, at AlO.
233 Vongs, supm note 91.
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50234
cover acupuncture. And a number of smaller health networks are covering tra-
ditional
235
Chinese herbal medicines as well. As more mainstream physicians are pre-
scribing
herbal treatments in conjunction with standard drugs, insurance companies,
HMO's, and other health organizations are agreeing that doctor knows best,
and are covering the costs.236
B. FDA Response to Traditional Chinese Medicine
Although Chinese herbal medicine can fall within the dietary supplement
classication, products that make specic claims to treat, cure, or prevent a
specic condition or ailment are technically drugs. Traditional Chinese herbal
medicine, however, like herbal medicine generally, has largely gone unregulated
by the FDA. Mr. William Goodrich, Chief Counsel of the FDA from 1939 to
1971 explained that the FDA stance towards Chinese herbal medicines during
his tenure was that of a wait-and-see posture: the regulation of such drugs was
not a priority unless they actually harmed
237
people. He claried this by saying that the FDA's budget in 1951 was about
$51
million, so given its limited resources, the FDA could not make the Chinese
medicines a priority unless they were harming a sizable number of people. Mr.
Goodrich noted that the number of complaints were small when he was in of-
ce. The FDA has commented on numerous occasions that its policy of only
investigating products that have spurred
234 Id.
235
236 Picker & McHugh, supra note 78.
237
Telephone Interview with Mr. William Goodrich, former Chief Counsel,
FDA, Jan. 14, 1997.
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complaints is still standing. In a Federal Register notice issued after the passage
of DHEA, the FDA stated:
In response to the DSHEA, FDA has also reassessed its general enforcement
priorities with respect to dietary supplements. FDA advises that in enforcing the
act with respect to these products, its primary focus is likely to be, as it always
has been, on safety concerns. The agency advises, however, that its regulatory
priorities are subject to adjustment in response to changing circumstances.239
However, when many deaths were reported in conjunction with the use of
ephedrine containing products, instead of using its enforcement authority
under DSHEA, the FDA issued a press release about the dangers of ephedrine,
inaccurately claiming that it lacked the authority to regulate dietary supple-
ments under DSHEA.240 Much attention had surrounded the ephedrine con-
taining supplements which promise a natural high, and which are sold as weight
loss aids, energy boosters, as well as an alternative to illegal
241
drugs. These products, with such seductive names as Herbal Ecstasy, Ulti-
mate
Xphoria, and Cloud 9, are derived from the Chinese herb ma huang, or
ephedra.242 Ma huang is one of the oldest herbs used in Chinese herbal medicine,
and has been used to treat asthma, clear blocked sinuses and increase alertness
and perception, although side eects like increased blood pressure have long
been known.243 In recent years, the FDA stated that at least 17 deaths and
over 600 reports of injuries have been associated with
238
Randy Bimestefer, FDA on Chinese Patent Medicines in Taking the Mystery
out of
Chinese Patent Medicines Website.
239
60 Fed.Reg. 19,597 (Apr. 19, 1995).
240
Pinco & Rubin, supia note 193, at 398.
241
Associated Press, US May Move on 'Natural High' Herbs Ephedrine is at
Issue in FDA Inquiry, The Boston Globe, Aug. 28, 1996.
242
Delores Kong, Herbal Ecstasy Attracts FDA Scrutiny after Reports of Deaths,
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From Ma Huang, a Chinese Herb with Ephedrine, The Fort Worth Star-Telegram,
Feb. 18, 1996.
243 Id.
44
52244
the use of ephedrine supplements. An FDA panel investigating ephedrine
products eventually called for curbing the sale of ephedrine products and pro-
posed also to reduce dosage recommendations, include label warnings, and con-
trol manufacturing. But some have alleged that the FDA refrained from using
its enforcement powers more vigorously so that Congress would become con-
vinced that stricter dietary supplement legislation was
245
necessary. It also indicates that the agency's need to proceed on a case-by-
case basis
slows the regulatory process, although the FDA has tried to combat that by
publishing consumer information on the broader issues of how to select alterna-
tive treatments.246
Chinese medicines that have elicited specic complaints or which consist of
components under investigation by the FDA are not allowed to be imported.
Mr. Sam Fine, former Associate Commissioner for Compliance, commented
that he remembered
discussion about the dangers of Chinese herbal medicines at the FDA, espe-
cially when
247
combined with American drugs. The FDA sought to control the import of
misbranded
drugs or drugs with false and misleading claims by working jointly with the
Bureau of Customs and stopping imports at the border, mainly through the
issuance of import alerts. But Mr. Fine echoed Mr. Goodrich's report that not
many complaints were made. One such recent import alert, updated December
18, 1996, called for the automatic detention of Chinese herbal medicines because
the products were new drugs without approved new drug applications and the
labeling lacked adequate directions for its intended use.248
24-4 Associated Press, supra note 241.
245 Pinco & Rubin, supra note 193, at 398.
246 David Taylor, supra note 93.
247
Telephone Interview with Mr. Sam Fine, former Associate Commissioner
for Compliance, FDA, Jan. 14, 1997.
248Chinese Herbal Medicines, Import Alert, Sept. 18, 1996, Website of the
FDA.
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53When the product was accompanied by drug claims, it was subject to both
charges, and
249
when not accompanied by drug claims, just the latter. It noted as the reason
for the alert that Chinese herbal medications have a history, dating back to 1974,
of containing
250
strong prescription drugs. The import alert stated that the medicines originated
from
several sources, and usually enter the country by air mail shipments to health
food stores,
oriental food stores, novelty shops, and individual consumers, with it occa-
sionally being
251
sold door-to-door. Actual enforcement against imported medicines already
in the
country is rarer, though in 1991 the FDA worked with the Federal Trade
Commission to
252
stop a New York rm's false advertising in Chinese. After receiving numerous
complaints, the FDA wamed the importer that the products were considered
drugs and so
they either had to stop making the claims or go through the appropriate
channels for a
253
drug application.
Dr. Lori Love, a doctor in the FDA's Center for Food Safety and Applied
Nutrition remarked that they do seriously evaluate some herbal products that
have
254
received adverse reports. The FDA focuses its limited resources on looking into
the most serious complaints and on issuing import bans on herbal products
found to be
dangerous, and so the FDA has stepped in to enforce safety and adulteration
guidelines
255
under DSHEA. But as the ephedrine controversy demonstrated, taking ac-
tions to stop
249 Id.
250 Id.
251
252
54Igor Cerny et al,. Reports from the Field, EDA&~nsum~r, April 1991, at
43.
253 Id.
254 Iritani, supra note 119.
255
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55products proven to be dangerous can be time consuming, and many injuries and
deaths can occur in the meantime.
Part of the answer seems to lie in what the FDA is doing now with foreign
pharmaceutical manufacturers. The FDA is working on testing herbal medicines
in conjunction with foreign companies before there are any signs of trouble.
Testing on puried forms of active compounds found in Chinese herbs have been
occurring for years now, such as when the FDA approved testing on humans of
an experimental AIDS drug derived from the root of a Chinese cucumber plant
in 1989.256 But recently the FDA has granted approval to foreign companies to
run trials not of isolated puried compounds, but of Chinese herbal medicines
entire. The Japanese pharmaceutical manufacturer Tsumura & Co. gamered
approval to run phase II clinical trials followed by a large-scale
double-blind comparative trial of a Chinese herbal medicine used for treating
chronic
257
rheumatoid arthritis. The FDA has also begun to grant approval of Chinese
manufactured herbal medicines. Hainan Hengxin Pharmaceutical Co. has
received FDA
approval for its ginseng pills, a preparation made from ginseng and other
Chinese herbs
258
which is used to stimulate the immune system. It has signed a supply contract
with a
259
U.S. corporation for $3.5 million.
256 FDA Approves Testing on Humans of AIDS Drug from Cucumber Plant,
HQusi~a Uir~nkk, April 28, 1989.
257 FDA Grants Tsumura Approval to Run Trials of Chinese Herbal Medicine,
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56V. Models for Reform
It is apparent that the FDA has begun to recognize the importance of taking
steps ex ante to safeguard the public health with regard to the consumption of
Chinese herbal medicine. But these measured steps are a far cry from a plan of
action for the FDA. A
1994 Oce of Alternative Medicine report noted that the current regulatory
mandate puts
260
the FDA in a dicult position. It is expected to 'protect the public' but
neither has the
expertise nor the resources to assess the catalogue of global herbal medicines.26'
The study suggests that instead of expecting the FDA to be an omnipotent pro-
tector, Congress should legislate a more educational, informational role for the
FDA, allowing
262
for such features as certication of herbal content and potency on labels.
Other nations
have taken similar steps with regard to the regulation of herbal medicines,
therefore it may be helpful to look at two models, one European, the other North
American, to observe how others are approaching this issue and to perhaps glean
insight into how the U.S. can better handle the matter.
1. G~rm~ny
Germany provides a useful model for reform with its long history of herbal
medicine use. Considerable research is done through universities or in-house
by
263
phannaceutical companies. The Bundesgesundheitsamt then examines the re-
search
and other sources of relevant information such as published reports and
pharmacological
260 Taylor, supra note 93.
261 Id.
262
263 Varro E. Tyler, Phytomedicines in Western Europe: Potential Impact
on Herbal Medicine in
the United States, 534 ACS SYMP. SERIES 25 (1993) at 27. $it~d.in
Cataxinos, supra note 147, at 578.
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57264
investigations before coming to a decision about the herbal medicine. Be-
cause the Bundesgesundheitsamt evaluates research literature, pharmaceutical
manufacturers are
encouraged to enter into research endeavors to advance a positive assessment
of their
265
product. In the U.S., the costs of the drug approval process substantially
diminish the
incentive of pharmaceutical companies to conduct the research and to in-
vest in the drug approval process. The diculty in patenting herbal medicines
has also been cited as a major disincentive for pharmaceutical companies. But
in Germany, since approval of herbal drugs depends on clinical and pharma-
cological literature as well as on the outcome of studies, the process has been
characterized as requiring reasonable certainty rather than the absolute proof'
of safety and ecacy required by the FDA.266 The
Bundesgesundheit created a special committee to regulate herbal medicines,
Commission
267
E. Commission E makes its determinations based on primarily bibliographic
information, experimental results, and other literature that sheds light on
the benets and
268
drawbacks of the medicine. After surveying all the data, Commission E issues
a
benet-to-risk ratio known as a monograph, which gives either a positive or
negative assessment of the product, a positive assessment resulting in marketing
approval.269
264k
265
Id. at 26.
267 Cataxinos, ~iipm note 147, at 579.
268 Paul Bergner, German Evaluation of Herbal Medicines, ikrkalgram, Winter
1994 at 17.
$it~din Cataxinos, supr~ note 147, at 580-1.
269 K. Keller, Results of the Revision of Herbal Drugs in the Federal Republic
of Germany with a
Special Focus on Risk Aspects, 13 Zeitschrift Fur Phvtotherapie 116, at 117
(1992); Paul Bergner, German Evaluation of Herbal Medicines, H~rba1gmm,
Winter 1994 at 17. BQIbsiX~d in Cataxinos, supra note 147, at 581.
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58270
Commission E has published 285 monographs since its inception in 1978.
Of those published, sixty-six percent document risk considerations, and of that
group, fty-eight monographs had a negative benet-to-risk ratio because of
insucient evidence of
271
ecacy, and so were banned from the market. Sixty-three monographs noted
contraindications based on possible allergic reactions, while twenty-four re-
stricted use
272
during pregnancy or lactation. Seven monographs contraindicated use for
those with
inammatory kidney disease and fteen contraindicated use for those with
gallstones.273
The evaluation of side eects is a key feature of the monographs, and thirty-
ve
274
monographs limit the period of use to curtail side eects. Herbal medicines
have been
banned by Commission E for being linked to unacceptable terminal risks,
such as a ban on all herbal medications containing the constituent aristolochic
acid, a known carcinogen.275
The situation in Germany prior to the Commission E monographs was some-
what similar to the situation in the U.S. today. There were conicting opinions
over whether the herbal medicines were safe or unsafe, and the German govern-
ment did not feel it had
270
Bergner, supra.note 268. ~it~din Cataxinos, suprn note 147. Under Ger-
many's Medicines Act of 1976, herbal products marketed prior to the Act re-
ceived provisional marketing authorization until April 1990, whereupon manu-
facturers had to present documentation conrming their product's safety and
ecacy under the new standards. 14. at 579.
271 Paul Bergner, supm note 268. $iI~din Cataxinos, supr~ note 147.
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275 Id. ~ The Federal Health Oce [through Commission E] Withdrew the
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Results of the Revision of Herbal Drugs in the Federal Republic of Germany
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sucient authority to present any one view as denitive. But consumers
needed some protection from drugs which were dangerous or misleading. The
use of Commission E monographs has allowed for the expression of varied views,
making for a more informed populace.277
2. ~
Canada provides an alternative model for reform of herbal medicine reg-
ulation. Canada regulates medicinal herbs as drugs, regardless of the claims
made.278 And
Canadian law requires medicinal herb labels to contain health claim infor-
mation for 279 cically, labels on Canadian herbal medicinal products must
state
consumers. Spe
280
indications for use and dosage requirements. One important dierence in the
drug
approval procedure for non-prescription drugs in Canada is that each drug
receives its own Drug Identication Number (DIN). A new drug application in-
cludes detailed information about the product's composition and dosage, phar-
macological or other
281
medical reference sources, and a draft label. Each drug, regardless of the number
of active ingredients, receives its own DIN. Therefore, medicinal herbs can be
approved for
use despite chemical complexity. This is in sharp contrast to the FDA ap-
proval process,
276
Bergner, supra note 268, at 64. S~l~ K. Keller, supra note 275, at 120.
B~thsiI~din
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Ariz. J. Int'l. & Comp. Law 545, at 546.
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278, at 546-7.
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281 Food and Drug Regulations C.0l.014.1, C.l0.003 (Can.), referred to in
HPB I.L. No. 771, Appendix A (Jan.5, 1990) (Can.) Cit~in Martin, supra note
278, at 571.
6051
61which requires reproducible results and does not allow for the approval of
complex chemical compounds like those found in traditional Chinese herbal
medicines.
In Canada, medicinal herbs are classied in two categories: the rst is for
herbs
282
listed in pharmacological reference books, and is adequate for DIN status.
These herbs
283
are what would be thought of as drugs in the common sense. The second
category
consists of herbs that may not have been used in Canada but have tradi-
tionally been used
284
elsewhere in the world. The Health Protection Branch, Canada's equivalent of
the
FDA, includes empirical or anecdotal testimony of the herb's ecacy as a
basis for DIN
285
approval. The acceptance of such non-scientic criteria is similar to one of
the
286
generally recognized as safe (GRAS) exceptions to food additives in the U.S.
The
Traditional Folk Medicines category has brought about better labeled herbal
products, but
the scope of permitted uses for the herbal products is limited to treating
minor, self-
287
limiting conditions, much as OTC drugs are used in the U.S. Hence, some-
times a
288
product that is not allowed in Canada can be found in the U.S.
$Qndu~n
In Canada, as well as in Germany, the history of an herbal drug's prior
use can be used as evidence of its safety. And in other European countries,
traditional use of herbal
282
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289
drugs is usually deemed sucient evidence of its safety and ecacy. France
ocially
recognizes more than 200 medicinal plants and provides specications re-
garding their
290
sale. An April 1995 article in the British Medical Joumal suggested special
licensing
of herbal medicines for treatment of minor illnesses, stating that the public
health is not well served when the strict application of conventional criteria to
herbal medicine products leaves most such products outside the purview of reg-
ulatory control.29' Although one could argue that these models allow too much
latitude to consumers, leaving problems to arise on the market as consumers use
these products, in the mistaken belief that the herbal medicines have in some
way been proven totally safe by passing the government approval process. But
that is not much worse than the state of herbal medicines in the U.S. today.
The FDA works on a passive system, and only when problems arise and formal
complaints led can any action be undertaken against the
292
manufacturer. The establishment of a separate oce to evaluate traditional
Chinese
herbal medicines and then to issue monographs gives consumers the infor-
mation needed to make better informed decisions, and will prevent purchases
of herbal medicines based on hearsay and speculation. The law as it stands to-
day discourages information dissemination lest the product fall under regulation
as a drug, and though DSHEA gives greater deference to dietary supplement
manufacturers in some of its labeling claims, it still falls short of providing the
information needed by the consuming public to make informed decisions about
Chinese herbal medicine.
53
64Chinese herbal medicines, if continued to be regulated under dietary supple-
ments, will need to substantiate structure/function statements and general well-
being claims.293
The standard should not be as high as those for drugs, given the disincentives
already
294
described, such as the inability to patent herbal medicines. Product-specic
substantiation may be one solution, where each product has to prove its
eectiveness for
its intended use through product-specic studies, unless the product is very
similar to
295
another that has already been proven eective.
There are other measures that could be adopted given the FDA's limited
resources. Instead of waiting for a series of complaints and then taking action,
which might come too late for many victims, as was the case with the ephedrine
products, perhaps the FDA could act sooner to target and seize non-compliant
Chinese herbal medicines on a small scale, thereby generating and using vari-
ous means of publicity to disseminate information about the product's dangers.
Licensing of Chinese herbal practitioners and pharmacists, as well as accredi-
tation of schools teaching Chinese herbal medicine are other steps that would
help ensure the health and safety of the consuming public.
The FDA's willingness to act will depend on how high it places Chinese
herbal medicines on its already long list of priorities. FDA' s agreements with
foreign pharmaceuticals like Tsumura & Co. and Hainan Hengxin Pharmaceu-
tical Co. seem to
292
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65demonstrate, however, that the FDA has begun to recognize the impact of
Chinese herbal medicine on America's health and pocketbook. By taking a
more proactive stance in exercising its enforcement powers, and by instituting a
separate oce with a monograph system similar to the European and Canadian
models, consumers will no longer be left to guess what is in the Chinese herbal
medicines they are taking.
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